Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 2Phase NA 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 1Leukemia 1Congenital Abnormalities 1

Interventions

Busulfan 3fludarabine phosphate 2Whole-Body Irradiation 2Melphalan 2Gemtuzumab 2Etoposide 2Cyclophosphamide 2tipifarnib 1sargramostim 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Immunologic Techniques 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Dexamethasone 1Daunorubicin 1DNA Methylation 1Cytogenetic Analysis 1Cytarabine 1Clofarabine 1Carboplatin 1Calcium Dobesilate 1Bone Marrow Transplantation 1Azacitidine 1Arsenic Trioxide 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Congenital Abnormalities × sargramostim × Clear all
NCT00630565 2024-01-29

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2/3 Terminated
12 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡